Give Brand Biologics, Biosimilars Same Naming Rules: Sandoz
The U.S. Food and Drug Administration should force brand-name biologics to use special nonproprietary names if it creates such a requirement for generic biosimilars, Sandoz Inc. said in a letter released...To view the full article, register now.
Already a subscriber? Click here to view full article